Revive Therapeutics authorizes 15.5 million incentive stock options

Revive Therapeutics Ltd., a life sciences company specializing in biodefence and pandemic preparedness, has announced that its Board of Directors authorized the grant of 15,500,000 incentive stock options.

The options are designated for key team members, including directors, officers, and consultants. Each option carries an exercise price of $0.05 per share and has a term of five years. The grants were issued under the company’s existing 10% rolling stock option plan and are subject to the terms of the plan and Canadian Securities Exchange requirements.